Mandate

Vinge has advised Pandox in connection with a directed share issue of SEK 2 billion

September 18, 2024

Vinge has advised the hotel property owner Pandox Aktiebolag (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 2 billion before transaction costs.

The company intends to use the proceeds to maintain the company’s strong financial position following hotel acquisitions in London and Edinburgh and to increase the company’s financial flexibility for additional property acquisitions and investments in existing properties. The Pandox share is listed on Nasdaq Stockholm.

Vinge’s team consisted of Jesper Schönbeck, Joel Magnusson, Adrian Filipovic and Maximilian Bengtsson.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025